IL201564A - 6s 70p kinase inhibitors - Google Patents

6s 70p kinase inhibitors

Info

Publication number
IL201564A
IL201564A IL201564A IL20156409A IL201564A IL 201564 A IL201564 A IL 201564A IL 201564 A IL201564 A IL 201564A IL 20156409 A IL20156409 A IL 20156409A IL 201564 A IL201564 A IL 201564A
Authority
IL
Israel
Prior art keywords
phenyl
add
compound
imidazol
trifluoromethyl
Prior art date
Application number
IL201564A
Other languages
English (en)
Hebrew (he)
Other versions
IL201564A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL201564A0 publication Critical patent/IL201564A0/en
Publication of IL201564A publication Critical patent/IL201564A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL201564A 2007-05-11 2009-10-15 6s 70p kinase inhibitors IL201564A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91733107P 2007-05-11 2007-05-11
PCT/US2008/062143 WO2008140947A1 (en) 2007-05-11 2008-05-01 P70 s6 kinase inhibitors

Publications (2)

Publication Number Publication Date
IL201564A0 IL201564A0 (en) 2010-05-31
IL201564A true IL201564A (en) 2014-08-31

Family

ID=39765082

Family Applications (1)

Application Number Title Priority Date Filing Date
IL201564A IL201564A (en) 2007-05-11 2009-10-15 6s 70p kinase inhibitors

Country Status (33)

Country Link
US (2) US8093383B2 (enExample)
EP (1) EP2148880B1 (enExample)
JP (1) JP5503532B2 (enExample)
KR (1) KR101088219B1 (enExample)
CN (1) CN101679439B (enExample)
AR (1) AR066344A1 (enExample)
AU (1) AU2008251692B2 (enExample)
BR (1) BRPI0811212A2 (enExample)
CA (1) CA2687265C (enExample)
CL (1) CL2008001230A1 (enExample)
CO (1) CO6241109A2 (enExample)
CR (1) CR11106A (enExample)
DK (1) DK2148880T3 (enExample)
DO (1) DOP2009000257A (enExample)
EA (1) EA016445B1 (enExample)
EC (1) ECSP099721A (enExample)
ES (1) ES2483726T3 (enExample)
GT (1) GT200900292A (enExample)
HR (1) HRP20140611T1 (enExample)
IL (1) IL201564A (enExample)
MA (1) MA31433B1 (enExample)
MX (1) MX2009012075A (enExample)
MY (1) MY154898A (enExample)
NZ (1) NZ580423A (enExample)
PE (1) PE20090887A1 (enExample)
PL (1) PL2148880T3 (enExample)
PT (1) PT2148880E (enExample)
RS (1) RS53451B (enExample)
SI (1) SI2148880T1 (enExample)
TN (1) TN2009000446A1 (enExample)
TW (1) TWI423805B (enExample)
UA (1) UA99284C2 (enExample)
WO (1) WO2008140947A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
US8252791B2 (en) * 2008-08-13 2012-08-28 Jenrin Discovery, Inc. Purine compounds as cannabinoid receptor blockers
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
BRPI0921888A2 (pt) * 2008-11-11 2015-12-29 Lilly Co Eli terapia de combinação de inibidor de egfr inibidor da p70 s6 quinase
EA018824B1 (ru) * 2008-11-11 2013-10-30 Эли Лилли Энд Компани КОМБИНИРОВАННАЯ ТЕРАПИЯ ИНГИБИТОРОМ КИНАЗЫ p70 S6 И ИНГИБИТОРОМ mTOR
PT2396307E (pt) 2009-02-11 2015-02-04 Merck Patent Gmbh Novas carboxamidas azaheterocíclicas de amino
ES2654332T3 (es) 2009-08-07 2018-02-13 Merck Patent Gmbh Nuevos compuestos azaheterocíclicos
AU2010310786B2 (en) * 2009-10-23 2014-03-27 Eli Lilly And Company AKT inhibitors
ES2670659T3 (es) 2010-02-03 2018-05-31 Signal Pharmaceuticals, Llc Identificación de mutación en LKB1 como un biomarcador predictivo para la sensibilidad a inhibidores de la quinasa TOR
EA028012B1 (ru) 2010-07-29 2017-09-29 Мерк Патент Гмбх Циклический амин-азагетероциклический карбоксамид
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
US8946247B2 (en) 2010-11-24 2015-02-03 Merck Patent Gmbh Quinazoline carboxamide azetidines
HRP20171655T1 (hr) 2011-09-12 2017-12-15 Merck Patent Gmbh Derivati aminopirimidina za upotrebu kao modulatori aktivnosti kinaze
PL2755965T3 (pl) 2011-09-12 2018-01-31 Merck Patent Gmbh Nowe aminy imidazolowe jako modulatory aktywności kinazowej
MX2015002887A (es) * 2012-09-06 2015-07-06 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
JP6280130B2 (ja) 2012-11-16 2018-02-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ キナーゼ活性のモジュレーターとしての新規イミダゾール−ピペリジニル誘導体
CA2890288A1 (en) 2012-11-16 2014-05-22 Merck Patent Gmbh Novel heterocyclic derivatives as modulators of kinase activity
KR20150090044A (ko) 2012-11-29 2015-08-05 메르크 파텐트 게엠베하 아자퀴나졸린 카복사미드 유도체
SG11201505999VA (en) * 2013-03-11 2015-08-28 Merck Patent Gmbh 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
KR102240356B1 (ko) 2013-04-17 2021-04-14 시그날 파마소티칼 엘엘씨 Ｔｏｒ 키나제 억제제와 5-치환된 퀴나졸리논 화합물을 포함하는 암 치료용 조합 요법
MX393164B (es) 2013-04-17 2025-03-21 Signal Pharm Llc Formulaciones farmacéuticas, proceso, formas sólidas y métodos de uso relacionados con 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-ii)piridin-3-ii)-3,4-dihidropirazino[2,3-b]pirazin-2(1h)-ona.
US9937169B2 (en) 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
AU2014254057A1 (en) 2013-04-17 2015-11-05 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
BR112015026247B1 (pt) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de compostos em combinação com um análogo de citidina, composição farmacêutica que os compreende, e kit
WO2014172426A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
BR112015026238A8 (pt) 2013-04-17 2019-12-24 Signal Pharm Llc composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
WO2015134536A1 (en) * 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN106456752B (zh) 2014-04-03 2020-11-20 默克专利股份公司 癌症治疗剂的组合
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2016040078A1 (en) * 2014-09-10 2016-03-17 Eli Lilly And Company Substituted phenyl imidazolyl piperidyl compounds as p70s6k1 inhibitors
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
CN110996955A (zh) 2017-06-22 2020-04-10 细胞基因公司 以乙型肝炎病毒感染为特征的肝细胞癌的治疗
US20240024324A1 (en) 2020-11-16 2024-01-25 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
CA2563699C (en) * 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
EP1848719B1 (en) 2004-12-28 2012-02-01 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
WO2007003960A1 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
EP2043655A2 (en) 2006-04-25 2009-04-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
US8093383B2 (en) 2012-01-10
MX2009012075A (es) 2009-11-19
KR101088219B1 (ko) 2011-11-30
JP2010526814A (ja) 2010-08-05
EA016445B1 (ru) 2012-05-30
TW200848053A (en) 2008-12-16
AU2008251692B2 (en) 2012-10-11
EP2148880A1 (en) 2010-02-03
CA2687265C (en) 2012-12-04
JP5503532B2 (ja) 2014-05-28
BRPI0811212A2 (pt) 2014-10-29
GT200900292A (es) 2011-06-24
SI2148880T1 (sl) 2014-07-31
IL201564A0 (en) 2010-05-31
DOP2009000257A (es) 2010-03-31
NZ580423A (en) 2012-02-24
TN2009000446A1 (en) 2011-03-31
PT2148880E (pt) 2014-08-28
HK1140767A1 (en) 2010-10-22
HRP20140611T1 (hr) 2014-08-15
UA99284C2 (ru) 2012-08-10
CN101679439A (zh) 2010-03-24
CN101679439B (zh) 2013-09-11
RS53451B (sr) 2014-12-31
CR11106A (es) 2010-04-12
EP2148880B1 (en) 2014-05-28
WO2008140947A1 (en) 2008-11-20
CA2687265A1 (en) 2008-11-20
US20090163714A1 (en) 2009-06-25
MY154898A (en) 2015-08-28
US20120071490A1 (en) 2012-03-22
EA200971051A1 (ru) 2010-06-30
PE20090887A1 (es) 2009-07-13
ES2483726T3 (es) 2014-08-07
MA31433B1 (fr) 2010-06-01
AU2008251692A1 (en) 2008-11-20
DK2148880T3 (da) 2014-06-16
AR066344A1 (es) 2009-08-12
TWI423805B (zh) 2014-01-21
CL2008001230A1 (es) 2009-05-22
PL2148880T3 (pl) 2014-10-31
CO6241109A2 (es) 2011-01-20
ECSP099721A (es) 2009-12-28
KR20100005710A (ko) 2010-01-15

Similar Documents

Publication Publication Date Title
CA2687265C (en) P70 s6 kinase inhibitors
ES2391704T3 (es) Inhibidores de cinasa AKT y P70 S6
AU2010310786B2 (en) AKT inhibitors
CA3189912A1 (en) Bicyclic compounds, compositions and use thereof
JP2023062074A (ja) Ｂ－ｒａｆキナーゼ阻害物質の結晶塩
WO2013024002A1 (en) PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE
CA3122136A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
IL294214B1 (en) Cyclic compounds and methods of using same
HK1140767B (en) P70 s6 kinase inhibitors
HK1158203B (en) Akt and p70 s6 kinase inhibitors

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees
KB Patent renewed
NP Permission for amending the patent specification granted (section 66, patents law 1967)
MM9K Patent not in force due to non-payment of renewal fees